Conferences - Results from #1000

Viewing 1001-1020 of 11869 articles

ASCO GU 2024: Phase 1B/2 Study of Pembrolizumab Plus Platinum/Etoposide and Platinum/Etoposide for Neuroendocrine Metastatic Prostate Cancer: Keynote-365 Cohort I

ASCO GU 2024: Subcutaneous Nivolumab Versus Intravenous Nivolumab in Patients With Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma: Pharmacokinetics, Efficacy, and Safety Results From CheckMate 67T

ASCO GU 2024: ARAMON: A Phase 2, Randomized, Open-Label Study Comparing Darolutamide vs Enzalutamide Monotherapy on Serum Testosterone Levels in Patients With Castration-Sensitive Prostate Cancer After Biochemical Recurrence

ASCO GU 2024: Phase III Randomized Trial of Stereotactic Ablative Radiotherapy for Oligometastatic Advanced Renal Carcinoma (EA8211-SOAR)

ASCO GU 2024: A Systematic Review: Are the Findings of Indirect Treatment Comparisons in Metastatic Hormone-Sensitive Prostate Cancer Consistent?

ASCO GU 2024: Real-World Homologous Recombination Repair Mutation Testing Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib in the United States

ASCO GU 2024: First-in-Human Safety, Imaging and Dosimetry of [68Ga]Ga-DPI-4452, a Novel CA IX-Targeting Peptide, in Patients with Clear Cell RCC

ASCO GU 2024: Subgroup Analyses of Efficacy Outcomes by Baseline Tumor Size in the Phase 3, Open-label CLEAR Trial

ASCO GU 2024: Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis

ASCO GU 2024: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC

ASCO GU 2024: Development of a Patient-Centered HRQOL Measure for Metastatic RCC: A Three-Phase Study

ASCO GU 2024: Utility of Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Disease Monitoring in Patients with Non-Seminomatous Germ-Cell Tumor

ASCO GU 2024: Longitudinal Tumor-Informed ctDNA Assay and Patient Outcomes in Testicular Cancer

ASCO GU 2024: Nivolumab plus Ipilimumab vs Sunitinib for First-Line Treatment of Advanced RCC: Long-Term Follow-up Data from the Phase 3 CheckMate 214 Trial

ASCO GU 2024: Nivolumab plus Cabozantinib vs Sunitinib for Previously Untreated Advanced RCC: Results from 55-Month Follow-up of the CheckMate 9ER Trial

ASCO GU 2024: Evaluating Prognostic Models for Stage I Seminoma Within the Randomised Trial of Imaging and Surveillance in Seminoma Testis (TRISST)

ASCO GU 2024: Cabozantinib plus Atezolizumab in Locally Advanced/metastatic Adrenocortical Carcinoma: Results from a Multi-Cohort Basket Phase II Trial, CABATEN/GETNE-T1914

ASCO GU 2024: Survivorship Issues Beyond 2 Years After Treatment in Testicular Germ Cell Tumors: Experience from a Large Center in the United Kingdom

ASCO GU 2024: The Impact of Immunotherapy-Based Regimens in Primary Renal Tumors

ASCO GU 2024: First-line Pembrolizumab plus Lenvatinib for Non–clear Cell RCC: Extended Follow-up of the Phase 2 KEYNOTE-B61 Study

46
47
48
49
50
51
52
53
54
55